Triple-negative breast cancer is the most malignant subtype of breast cancer with negative expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), and is associated with poor therapeutic response and prognosis. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.